Navigation Links
Inhaled Corticosteroids Reduce Death in Patients with COPD

Patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids may have a significantly decreased mortality risk// , according to a new study published in the September issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP). New research shows that patients who received inhaled corticosteroids within 30 days of hospital discharge had a 25 percent reduced all-cause mortality rate. Cardiovascular-related death alone in patients using steroids paired with beta-agonists was reduced by 38 percent.

“COPD is an undertreated lung disease that has associated heart disease,” said author Christine Macie, MD, FCCP, Cambridge Hospital, Ontario, Canada. “Controversy exists with respect to the effect of inhaled corticosteroids on mortality. Our study examined the effect of inhaled corticosteroids on survival, and results suggest that the survival is longer in patients using inhaled corticosteroids.”

From April 1995 to March 2000, Dr. Macie and researchers from the University of Manitoba, Winnipeg, Canada, assessed the influence of inhaled corticosteroids on mortality in patients, 90 to 365 days posthospital discharge for COPD. Researchers collected patient information from a comprehensive database, excluding those who died within 90 days. In total, 4,987 patients were split into two groups: those between the ages of 35 to 64 (965) and those 65-years-old or older (4,002). Within those groups, patients who received inhaled corticosteroids within 90 days of hospital discharge were compared with those who did not.

Dr. Macie and colleagues found that the mortality rates in patients 65+ who received inhaled corticosteroids were 11.7 percent, compared with 13.1 percent for those who did not. Patients in the younger group showed even greater results, with a mortality rate of 3.0 percent for patients receiving inhaled corticosteroids within 90 days, compared with 6.0 percent for those who d id not, providing a mortality reduction rate of 53 percent. When patients who received steroids in the year prior were removed from the analysis, mortality was reduced by 34 percent. Researchers attribute this finding to multifactorial reasons, including reductions in exacerbations of the disease and suppression of inflammation.

Researchers also found a 23 percent reduced risk of death when comparing the effects of inhaled steroids with bronchodilators in patients in the 65+ group. In all cases, the most significant results were found when inhaled corticosteroids were administered within the first 30 days following hospital discharge.

“Our results indicate that the effect of inhaled corticosteroids is relatively short-term and that those currently using it are relatively better protected, ” said Dr. Macie. “Inhaled corticosteroids should be prescribed as soon as clinically indicated. By treating COPD with inhaled corticosteroids, we have the potential to reduce the effect and prolong life.”

“The findings from this study are intriguing for clinicians and point to the need for further research to define the role and mechanisms of the effect of inhaled corticosteroids on both cardiovascular and respiratory mortality,” said W. Michael Alberts, MD, FCCP, President of the ACCP.

Source-Newswie
SRM
'"/>




Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch ... for colleges and universities at the APPA 2017 Annual Conference and Exhibition ... tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... 21, 2017 , ... “Kids aren't born knowing how to regulate their emotions ... Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help with that ... July 21st. , The kit uses colorful, engaging and educational illustrations and games ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: